<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407874</url>
  </required_header>
  <id_info>
    <org_study_id>BCX4208-204</org_study_id>
    <nct_id>NCT01407874</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency</brief_title>
  <official_title>A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol
      in subjects with moderate renal insufficiency.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol in subjects with moderate renal insufficiency by assessment of percent change from baseline in CD4+ lymphocytes at Day 85.</measure>
    <time_frame>85 days</time_frame>
    <description>Level of CD4+ lymphocytes to be measured at Day 85 compared to baseline.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <condition>Arthritis</condition>
  <condition>Joint Disease</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo + Allopurinol 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulodesine (BCX4208) 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCX4208 5mg + Allopurinol 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulodesine (BCX4208) 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCX4208 10mg + Allopurinol 200mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral dose administered daily for 84 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulodesine (BCX4208) 5 mg</intervention_name>
    <description>Oral dose administered daily for 84 days.</description>
    <arm_group_label>Ulodesine (BCX4208) 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulodesine (BCX4208) 10 mg</intervention_name>
    <description>Oral dose administered daily for 84 days.</description>
    <arm_group_label>Ulodesine (BCX4208) 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 to &lt; 70 years

          2. Have read and signed the Informed Consent Form

          3. Documented diagnosis of gout

          4. Documented moderate renal insufficiency

          5. Calculated creatinine clearance of ≥ 30 and &lt; 60 mL/min

          6. Willing and able to take allopurinol 200 mg every day for the duration of the
             Treatment

          7. Female participants must be sexually abstinent for 4 weeks prior to Day 1 and continue
             abstinence for 4 weeks after completion of study drug, surgically sterile,
             postmenopausal,use oral contraceptives for three months prior to study drug dosing
             through 4 weeks after completion of study drug, an intrauterine device for 8 weeks
             prior to study drug dosing through 4 weeks after completion of study drug,double
             barrier contraception method for 4 weeks prior to study drug dosing through 4 weeks
             after completion of study drug administration

          8. Male participants must be sexually abstinent for 4 weeks prior to Day 1 and continue
             abstinence through 90 days after completion of study drug, be &gt; 1 year postvasectomy,
             agree to use a condom with spermicide from the start of study drug dosing through 90
             days after completion of study drug.

          9. Willing and able to provide authorization for the use and disclosure of personal
             health information in accordance with Health Insurance Portability and Accountability
             Act (HIPAA)

        Exclusion Criteria:

          1. Unable to tolerate allopurinol 200 mg every day

          2. Prior randomization in a clinical study with BCX4208

          3. Unstable cardiac disease such as: unstable angina, symptomatic arrhythmia, signs or
             symptoms compatible with NYHA Class III or Class IV functional status for congestive
             heart failure or angina, history of long QT syndrome, or QTc interval &lt; 350 msec or &gt;
             475 msec

          4. Poorly controlled hypertension

          5. History of severe renal insufficiency

          6. Alanine aminotransferase or aspartate aminotransferase values &gt; 2.0 x upper limit of
             normal

          7. CD4+ cell counts by flow cytometry &lt; 500 cells/mm3

          8. Hemoglobin &lt; 10 g/dL or &gt; 18 g/dL (males) or &lt; 10 g/dL or &gt; 17 g/dL (females)

          9. White blood cell count &lt; 3.7 x 109/L or &gt; 11 x 109/L

         10. Female subjects who are pregnant, breastfeeding, or planning a pregnancy within the
             next 4 months

         11. Positive serology for hepatitis B surface antigen or hepatitis C antibody or HIV type
             1

         12. Immunocompromised due to illness or organ transplant

         13. Use of systemic immunosuppressive medications or disease-modifying antirheumatic drugs

         14. Use of azathioprine or 6-mercatopurine within 14 days of first dose of allopurinol

         15. Use of hydrochlorothiazide in doses &gt; 50 mg per day

         16. Planned use of herbal or dietary supplements

         17. Recipient of any live or attenuated vaccine within 6 weeks of Screening

         18. Planned use of uric acid-lowering drugs other than allopurinol

         19. Use of systemic corticosteroids within 4 weeks prior to Day 1

         20. Use of any investigational drug within 30 days prior to signing the ICF

         21. History of clinically significant and relevant drug allergies

         22. History of chronic or recurrent infections

         23. History of any type of cancer not successfully treated or in full remission for 12
             months prior to Screening

         24. History of alcohol or drug abuse within the year prior to the signing of the ICF, or
             current evidence of substance dependence or abuse

         25. Use of other prohibited medications within the timeframes specified in the protocol

         26. Other medical conditions which, in the opinion of the Principal Investigator, would
             jeopardize the safety of the study subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Hollister, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BioCryst Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oldsmar</city>
        <state>Florida</state>
        <zip>34677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <disposition_first_submitted>October 4, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>October 4, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 28, 2013</disposition_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gout</keyword>
  <keyword>Hyperuricemia</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint Disease</keyword>
  <keyword>Allopurinol</keyword>
  <keyword>Renal Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Gout</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

